Erratum: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012 (Journal of Infectious Diseases (2005) 192:1 (24-29) DOI: 10.1086/430742);Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012

Journal of Infectious Diseases

Volumn 192, Issue 1, 2005, Pages 24-29

  Flys, Tamara ^a   Nissley, Dwight V ^b,c   Claasen, Cassidy W ^c   Jones, Dana ^a   Shi, Chanjuan ^a   Guay, Laura A ^a   Musoke, Philippa ^d   Mmiro, Francis ^d   Strathern, Jeffrey N ^c   Jackson, J Brooks ^a   Eshleman, James R ^a   Eshleman, Susan H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Centre for Basic Research   (Uganda)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MUTATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS TYPING;

EID: 20844437104     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiz524     Document Type: Erratum

References (16)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999; 354:795-802.
2. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-30.
3. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-7.
4. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-40.
5. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther 2003; 8:S85.
6. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine [abstract ThOrB1353]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok, Thailand, 2004). Vol. 2. Geneva: International AIDS Society, 2004:325.
7. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Human Retroviruses 2004; 20:595-7.
8. Shi C, Eshleman SH, Jones D, et al. LigAmp: sensitive detection of single nucleotide differences. Nature Methods 2004; 1:141-7.
9. Nissley DV, Boyer PL, Garfinkel DJ, Hughes SH, Strathern JN. Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1998; 95: 13905-10.
10. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78:603-11.
11. Little SJ, Dawson K, Hellmann NS, Richman DD, Frost SDW. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring therapy. Antivir Ther 2003; 8:S129.
12. Palmer S, Boltz V, Maldarelli F, et al. Persistence of NNRTI-resistant variants after single-dose nevirapine in HIV-1 subtype C-infected women [abstract 101]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:101.
13. Loubser S, Balfe P, Sherman G, et al. Sensitive real-time PCR quantification of 103N resistance mutants following single-dose treatment with nevirapine [abstract 102]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:102.
14. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002; 186:181-8.
15. Chalermchokcharoenkit A, Asavarpiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results [abstract 96]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA, 2004). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:111.
16. McIntyre J, Martinson N, Boltz V, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus [abstract LbOrB09]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok, Thailand, 2004). Suppl. Geneva: International AIDS Society, 2004:32.